But Pfizer’s decision has dismayed public-health advocates. DNDi’s inability to obtain medicine for clinical trials compounds ongoing inequities in access to vaccines and treatments, including Paxlovid, in low- and middle-income countries, says Brook Baker, a law professor at Northeastern University in Boston, Massachusetts, who specializes in global access to medicines and vaccines. “This is a […]